News

Generic antiemetic now available in US


 

Photo from Business Wire

Fresenius Kabi’s Palonosetron Hydrochloride Injection

Palonosetron Hydrochloride Injection, a generic alternative to Aloxi®, is now available in the US.

Fresenius Kabi’s Palonosetron Hydrochloride Injection is a 5-HT3 serotonin receptor that is approved for the prevention of nausea and vomiting in certain adults.

Palonosetron Hydrochloride Injection is available in a single-dose vial (0.25 mg per 5 mL).

In the US, Palonosetron Hydrochloride Injection is approved for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

The drug is also approved for the prevention of acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy.

And Palonosetron Hydrochloride Injection is approved for the prevention of post-operative nausea and vomiting for up to 24 hours after surgery. Efficacy beyond 24 hours has not been demonstrated.

The full prescribing information for Palonosetron Hydrochloride Injection can be found on the Fresenius Kabi website.

Recommended Reading

Updated CLL guidelines incorporate a decade of advances
MDedge Hematology and Oncology
Age and race affect access to myeloma treatment
MDedge Hematology and Oncology
Do industry payments increase prescribing for some targeted therapies?
MDedge Hematology and Oncology
Ponatinib bests older TKIs against Ph+ALL
MDedge Hematology and Oncology
Gene variants linked to survival after HSCT
MDedge Hematology and Oncology
Duvelisib NDA granted priority review
MDedge Hematology and Oncology
Health Canada approves product for adult ALL
MDedge Hematology and Oncology
Team maps genetic evolution of T-ALL subtype
MDedge Hematology and Oncology
Project provides ‘unprecedented understanding’ of cancers
MDedge Hematology and Oncology
Drug receives priority review for HCL
MDedge Hematology and Oncology